Quality of life in schizophrenia patients not taking medication

Not yet recruiting

Conditions: Schizophrenia, unspecified,

Registration Number: CTRI/2024/09/073729

Lead Sponsor: DATTA MEGHE INSTITUTE OF HIGHER EDUCATION AND RESEARCH

Brief Summary: Schizophrenia is a mental disorder that disruptsthought processes, perceptions, emotional responsiveness, and socialinteractions. Although the course of schizophrenia differs from person toperson, it is usually chronic and can be severe and disabling, resulting insignificant impairments in quality of life. As treatment As approaches evolved, more emphasis was placed on re-integrating patients intotheir psychosocial environments rather than simply monitoring psychoticsymptoms. With the increasing availability of a wide range of drugs to treatmental illnesses, psychotropic medications are now an essential component inthe treatment of patients with severe mental disorders. In For patients with schizophrenia, quality of life is an important aspect ofrecovery. Quality of life (QoL) is a term that refers to the wellbeing of apopulation or an individual in terms of both positive and negative aspects oftheir existence at a particular time. Personal health (physical,mental and spiritual), relationships, education status, work environment,social status, wealth, a sense of security and safety, freedom, and autonomy indecision-making, social-belonging, and their physical surroundings are examplesof common aspects of QoL.According to Boyer et al., one of the most important variables indetermining the recurrence of schizophrenia is QoL. The better the patient’s quality of life, the less likely they are to relapse within two years.Thedevelopment of second-generation antipsychotics raised expectations that thesemedications would improve quality of life more than traditional antipsychotics. Nearly one-third of people who suffer major psychiatric disorders globally endup with a long-term disability and dependency. However, very fewIndian studies have compared the change in quality-of-life following treatmentwith typical and atypical antipsychotics.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 90

Inclusion Criteria

INCLUSION CRITERIA: Patients who are clinically diagnosed to have Schizophrenia using the International Classification of Diseases 11th revision (ICD-11) research criteria Patients within the age group of 18 to 65 years.
The patient should be able to give written, informed consent.
Patient should be non-compliant at least for a period of 2 months.
Patients should be compliant at least for a period of a year.

Exclusion Criteria

Subjects are not willing to give written informed consent.
Patients who are acutely ill or are not able to cooperate with the study Patients who have a history of developmental delay or any other major organic brain pathology.
Patient who had history of head injury.
Patients who have been non- compliant for less than 2 months.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A comprehensive outcome of poor compliance to Treatment of Schizophrenia on the outcome of disease.	Assessments will be done at 6 months

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (1): Acharya Vinobha Bhave Rural Hospital
🇮🇳
Wardha, MAHARASHTRA, India
Acharya Vinobha Bhave Rural Hospital
🇮🇳Wardha, MAHARASHTRA, India
Dr Kotla Rishitha
Principal investigator
7095726957
kotla.rishitha@gmail.com